KFAS
VERA icon

Keating Financial Advisory Services’s Vera Therapeutics VERA Stock Holding History

Keating Financial Advisory Services’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129 Sell
3
-3
-50% -$112 ﹤0.01% 2460
2026
Q1 		$241 Buy
+6
New +$259 ﹤0.01% 2353

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Keating Financial Advisory Services's VERA Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its Vera Therapeutics (VERA) stake by 50% in Q2 2026, selling an estimated $112 and leaving 3 shares worth $129. The position accounts for ﹤0.01% of the portfolio, ranked #2460.

Keating Financial Advisory Services first reported a position in VERA in Q1 2026 and has held it in 2 quarters since. The position peaked at $241 in Q1 2026. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Keating Financial Advisory Services held 3 shares of Vera Therapeutics worth $129 as of Q2 2026.
  • Keating Financial Advisory Services sold 3 Vera Therapeutics shares in Q2 2026, an estimated $112.
  • Vera Therapeutics made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2460 holding.
  • Keating Financial Advisory Services first reported a position in Vera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Keating Financial Advisory Services's Vera Therapeutics position peaked at $241 in Q1 2026.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.